Fort St James Nickel Corp
Change company Symbol lookup
Select an option...
OARFF Fort St James Nickel Corp
NAAS Naas Technology Inc
OIG Orbital Infrastructure Group Inc
FPI Farmland Partners Inc
HNST Honest Company Inc
ONTF ON24 Inc
ATAI ATAI Life Sciences NV
FTS Fortis Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
Go


Based in Canada
Company profile

Fort St. James Nickel Corp. is a Canada-based junior mineral exploration company. The Company's primary business is the acquisition of exploration and evaluation of mineral properties in North America. The Company owns interest in the Kilometre 26 Project, a group of mineral claims located approximately 50 kilometers (km) northwest of Fort St. James in central British Columbia. This project consists of approximately 5,778 hectares in the Omineca Mining Division. It also owns interest in the Porcupine property located in the province of New Brunswick and Nepisiguit Base Metal-Precious Metal Property located within the Bathurst Mining Camp of northern New Brunswick.

Closing Price
$0.06
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.

3:18 pm ET August 8, 2022 (PR Newswire) Print

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $68.50 in cash for each share of Global Blood common stock owned. The transaction is valued at approximately $5.4 billion.

https://mma.prnewswire.com/media/1424445/WeissLaw_LLP_Logo.jpg

If you own Global Blood shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/gbt Or please contact:Joshua Rubin, Esq.Weiss Law 305 Broadway, 7th FloorNew York, NY 10007(212) 682-3025(888) 593-4771stockinfo@weisslawllp.com

Weiss Law is investigating whether (i) Global Blood's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $68.50 per-share merger consideration adequately compensates Global Blood's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, at least one analyst set a price target for the Company of $100 per share, $31.50 above the per-share merger consideration.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

https://c212.net/c/img/favicon.png?sn=DC38996&sd=2022-08-08

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-global-blood-therapeutics-inc-301601690.html

SOURCE Weiss Law

https://rt.prnewswire.com/rt.gif?NewsItemId=DC38996&Transmission_Id=202208081518PR_NEWS_USPR_____DC38996&DateId=20220808

comtex tracking

COMTEX_411858691/1005/2022-08-08T15:18:07

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.